Mechanisms of reaginic hypersensitivity: a review

KIMISHIGE ISHIZAKA, JERUKO ISHIZAKA

Research output: Contribution to journalArticle

Abstract

Gamma E antibodies represent the major part of human reaginic antibodies. The antibodies sensitize human and monkey skin, human leucocytes and primate lung tissues. The allergen‐γE antibody reaction mediates the release of histamine from human leucocytes and both histamine and SRS‐A from monkey lung tissues. The immunoglobulin is formed in lymphoid tissues especially those In respiratory and gastrointestinal tracts. Turnover rate of this protein in the blood is only 2–3 days, suggesting that human reaginic antibodies are being formed continuously in atopic patients. However, γE injected into normal skin sites is retained for a long time. The half‐time of loss of the immunoglobulin was 9–14 days in human skin and 8–10 days in monkey skin. Evidence has accumulated that IgE combines with target cells through the Fc portion of the molecules. The Fc fragments block passive sensitization of human skin with reaginic antibodies and passively sensitize human leucocytes and monkey lung tissue for reversed type reactions. Target cells in human leucocytes were identified as basophil leucocytes. The immunoglobulin binds with tissue mast cells upon passive sensitization. The initial step in reaginic hypersensitivity seems to be the bridging of cell‐bound IgE with allergen. It appears that the interaction between the IgE molecules or consequent structural changes in the Fc portion of the molecules may induce enzymatic sequences leading to the release of histamine and SRS‐A. The enzyme activated by the allergen‐γE antibody reaction is not the complement system. The biochemical pathways subsequent to the γE‐γE interaction and prior to the release of chemical mediators are unknown. However, evidence has accumulated that the β adrenergic system or the intracellular accumulation of cyclic‐AMP regulate the biochemical pathways.

Original languageEnglish (US)
Pages (from-to)9-24
Number of pages16
JournalClinical and Experimental Allergy
Volume1
Issue number1
DOIs
StatePublished - 1971

Fingerprint

Hypersensitivity
Antibodies
Leukocytes
Haplorhini
Skin
Immunoglobulin E
Immunoglobulins
Histamine Release
Lung
Immunoglobulin Fc Fragments
Basophils
Lymphoid Tissue
Mast Cells
Respiratory System
Adrenergic Agents
Allergens
Histamine
Primates
Gastrointestinal Tract
Blood Proteins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mechanisms of reaginic hypersensitivity : a review. / ISHIZAKA, KIMISHIGE; ISHIZAKA, JERUKO.

In: Clinical and Experimental Allergy, Vol. 1, No. 1, 1971, p. 9-24.

Research output: Contribution to journalArticle

ISHIZAKA, KIMISHIGE ; ISHIZAKA, JERUKO. / Mechanisms of reaginic hypersensitivity : a review. In: Clinical and Experimental Allergy. 1971 ; Vol. 1, No. 1. pp. 9-24.
@article{09189a04b5a045e9a98f52bd7cc9f805,
title = "Mechanisms of reaginic hypersensitivity: a review",
abstract = "Gamma E antibodies represent the major part of human reaginic antibodies. The antibodies sensitize human and monkey skin, human leucocytes and primate lung tissues. The allergen‐γE antibody reaction mediates the release of histamine from human leucocytes and both histamine and SRS‐A from monkey lung tissues. The immunoglobulin is formed in lymphoid tissues especially those In respiratory and gastrointestinal tracts. Turnover rate of this protein in the blood is only 2–3 days, suggesting that human reaginic antibodies are being formed continuously in atopic patients. However, γE injected into normal skin sites is retained for a long time. The half‐time of loss of the immunoglobulin was 9–14 days in human skin and 8–10 days in monkey skin. Evidence has accumulated that IgE combines with target cells through the Fc portion of the molecules. The Fc fragments block passive sensitization of human skin with reaginic antibodies and passively sensitize human leucocytes and monkey lung tissue for reversed type reactions. Target cells in human leucocytes were identified as basophil leucocytes. The immunoglobulin binds with tissue mast cells upon passive sensitization. The initial step in reaginic hypersensitivity seems to be the bridging of cell‐bound IgE with allergen. It appears that the interaction between the IgE molecules or consequent structural changes in the Fc portion of the molecules may induce enzymatic sequences leading to the release of histamine and SRS‐A. The enzyme activated by the allergen‐γE antibody reaction is not the complement system. The biochemical pathways subsequent to the γE‐γE interaction and prior to the release of chemical mediators are unknown. However, evidence has accumulated that the β adrenergic system or the intracellular accumulation of cyclic‐AMP regulate the biochemical pathways.",
author = "KIMISHIGE ISHIZAKA and JERUKO ISHIZAKA",
year = "1971",
doi = "10.1111/j.1365-2222.1971.tb02444.x",
language = "English (US)",
volume = "1",
pages = "9--24",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Mechanisms of reaginic hypersensitivity

T2 - a review

AU - ISHIZAKA, KIMISHIGE

AU - ISHIZAKA, JERUKO

PY - 1971

Y1 - 1971

N2 - Gamma E antibodies represent the major part of human reaginic antibodies. The antibodies sensitize human and monkey skin, human leucocytes and primate lung tissues. The allergen‐γE antibody reaction mediates the release of histamine from human leucocytes and both histamine and SRS‐A from monkey lung tissues. The immunoglobulin is formed in lymphoid tissues especially those In respiratory and gastrointestinal tracts. Turnover rate of this protein in the blood is only 2–3 days, suggesting that human reaginic antibodies are being formed continuously in atopic patients. However, γE injected into normal skin sites is retained for a long time. The half‐time of loss of the immunoglobulin was 9–14 days in human skin and 8–10 days in monkey skin. Evidence has accumulated that IgE combines with target cells through the Fc portion of the molecules. The Fc fragments block passive sensitization of human skin with reaginic antibodies and passively sensitize human leucocytes and monkey lung tissue for reversed type reactions. Target cells in human leucocytes were identified as basophil leucocytes. The immunoglobulin binds with tissue mast cells upon passive sensitization. The initial step in reaginic hypersensitivity seems to be the bridging of cell‐bound IgE with allergen. It appears that the interaction between the IgE molecules or consequent structural changes in the Fc portion of the molecules may induce enzymatic sequences leading to the release of histamine and SRS‐A. The enzyme activated by the allergen‐γE antibody reaction is not the complement system. The biochemical pathways subsequent to the γE‐γE interaction and prior to the release of chemical mediators are unknown. However, evidence has accumulated that the β adrenergic system or the intracellular accumulation of cyclic‐AMP regulate the biochemical pathways.

AB - Gamma E antibodies represent the major part of human reaginic antibodies. The antibodies sensitize human and monkey skin, human leucocytes and primate lung tissues. The allergen‐γE antibody reaction mediates the release of histamine from human leucocytes and both histamine and SRS‐A from monkey lung tissues. The immunoglobulin is formed in lymphoid tissues especially those In respiratory and gastrointestinal tracts. Turnover rate of this protein in the blood is only 2–3 days, suggesting that human reaginic antibodies are being formed continuously in atopic patients. However, γE injected into normal skin sites is retained for a long time. The half‐time of loss of the immunoglobulin was 9–14 days in human skin and 8–10 days in monkey skin. Evidence has accumulated that IgE combines with target cells through the Fc portion of the molecules. The Fc fragments block passive sensitization of human skin with reaginic antibodies and passively sensitize human leucocytes and monkey lung tissue for reversed type reactions. Target cells in human leucocytes were identified as basophil leucocytes. The immunoglobulin binds with tissue mast cells upon passive sensitization. The initial step in reaginic hypersensitivity seems to be the bridging of cell‐bound IgE with allergen. It appears that the interaction between the IgE molecules or consequent structural changes in the Fc portion of the molecules may induce enzymatic sequences leading to the release of histamine and SRS‐A. The enzyme activated by the allergen‐γE antibody reaction is not the complement system. The biochemical pathways subsequent to the γE‐γE interaction and prior to the release of chemical mediators are unknown. However, evidence has accumulated that the β adrenergic system or the intracellular accumulation of cyclic‐AMP regulate the biochemical pathways.

UR - http://www.scopus.com/inward/record.url?scp=84990406765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990406765&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2222.1971.tb02444.x

DO - 10.1111/j.1365-2222.1971.tb02444.x

M3 - Article

AN - SCOPUS:84990406765

VL - 1

SP - 9

EP - 24

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 1

ER -